Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.

doi:10.1038/s41591-018-0024-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.

Nature medicine - 1 Jul 2018

Ruess Dietrich A, Heynen Guus J, Ciecielski Katrin J, Ai Jiaoyu, Berninger Alexandra, Kabacaoglu Derya, Görgülü Kivanc, Dantes Zahra, Wörmann Sonja M, Diakopoulos Kalliope N, Karpathaki Angeliki F, Kowalska Marlena, Kaya-Aksoy Ezgi, Song Liang, van der Laan Eveline A Zeeuw, López-Alberca María P, Nazaré Marc, Reichert Maximilian, Saur Dieter, Erkan Mert M, Hopt Ulrich T, Sainz Bruno, Birchmeier Walter, Schmid Roland M, Lesina Marina, Algül Hana

Abstract excerpt

The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors1. Its requirement for complete RAS-MAPK activation and its role as a negative regulator of JAK-STAT signaling have established SHP2 as an essential player in oncogenic signaling pathways1-7. Recently, a novel potent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinogenesis

Share to Disease Progression

Share to Mitogen-Activated Protein Kinase Kinases

Share to Pancreatic Neoplasms

Share to Protein Kinase Inhibitors

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed

Identifiers

PMID: 29808009
DOI: 10.1038/s41591-018-0024-8

Genes

KRAS
PTPN11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.PMID 29808009Read ↗

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.Semantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.Semantic proximity Read ↗

Developing SHP2-based combination therapy for KRAS-amplified cancer.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.Semantic proximity Read ↗

SHP2 Inhibition Abrogates Adaptive Resistance to KRAS <sup>G12C</sup> -Inhibition and Remodels the Tumor Microenvironment of <i>KRAS</i> -Mutant TumorsSemantic proximity Read ↗

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.Semantic proximity Read ↗

The role of Shp2 (PTPN11) in cancer.Semantic proximity Read ↗

The tyrosine phosphatase Shp2 (PTPN11) in cancer.Semantic proximity Read ↗

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.Semantic proximity Read ↗

Strategies to overcome drug resistance using SHP2 inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.